What do a Boston psychiatrist, a Brown University administrator, and a diminutive, legally blind district attorney all have in common? All three believed something was amiss with the marketing of selective serotonin release inhibitors (SSRIs) for children and adolescents. All three serve as the protagonists in Alison Bass’s new book “Side Effects: A Prosecutor, a Whistleblower, and…more...

Is there a more wasteful federal program than NASA? Does it matter if a robot can land on some planet and take a picture of itself digging a small hole? It’s clear that NASA is both useless and popular. Which is the opposite of the pharmaceutical industry: indispensible and unpopular. NASA gets it. NASA understands public relations.…more...

Johnson & Johnson selected ArisGlobal as its drug safety solution, a significant endorsement for the pharmacovigilance software house.  “With ArisGlobal’s ARISg robust feature set, flexible data model, intuitive user interface and ability to integrate with our key systems, Johnson & Johnson will incorporate this solution into our existing enterprise-wide processes, knowing that they have the ability to…more...

Should a clinical trial unfold like a beloved family recipe, by rote from a time-honored template passed down through generations of trial operations managers? That is one approach in the industry. Or should the process be dynamic and interactive, driven by actual and simulated data? That’s the modus operandi of DecisionView, a 50-person firm out of San…more...